Search

everythinglearnresearchcommunity

for

Search:↓

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

The formula YH0618 can reduce the harmful side effects of the chemotherapy drug Doxorubicin and protect healthy cells.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Upadacitinib successfully regrew hair in a child with alopecia universalis and specific genetic mutations.

Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.

Clofazimine effectively treated ashy dermatosis in a patient.

JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.

The formulated gel is a promising treatment for alopecia areata.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Tofacitinib effectively treats Alopecia Areata.

Golvatinib shows promise as a treatment for Omicron in elderly patients.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Minoxidil may protect nerves and improve hair quality during paclitaxel treatment.

Ruxolitinib cream shows promise for vitiligo, and early melanoma diagnosis is crucial.

A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

The nanoparticles show promise for cancer treatment and diagnosis with fewer side effects.

Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.

The treatment was ineffective in humans.

Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.

Some drugs used to treat inflammation may cause hair loss.